Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review.
Infect Dis (Lond)
; 53(3): 206-211, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-33295821
ABSTRACT
INTRODUCTION:
Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections. CASE PRESENTATION We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision.CONCLUSIONS:
Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pseudomonas aeruginosa
/
Preparações Farmacêuticas
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article